| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Ludo Van Den Bosch | Q32426032 |
| P2093 | author name string | Robberecht W | |
| Van Damme P | |||
| Dewil M | |||
| P2860 | cites work | A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2 | Q24291755 |
| A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis | Q24304337 | ||
| DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4) | Q24533845 | ||
| Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis | Q28131805 | ||
| Amyotrophic lateral sclerosis-linked glutamate transporter mutant has impaired glutamate clearance capacity | Q28141147 | ||
| The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis | Q28190263 | ||
| From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS | Q28206361 | ||
| Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam | Q28210145 | ||
| Glutamate receptors: RNA editing and death of motor neurons | Q28247026 | ||
| Expression of the glial glutamate transporter EAAT2 in the human CNS: an immunohistochemical study | Q28260466 | ||
| Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis | Q28267385 | ||
| Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis | Q28270636 | ||
| RNA editing in brain controls a determinant of ion flow in glutamate-gated channels | Q28279138 | ||
| Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis | Q28335672 | ||
| Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models | Q28572282 | ||
| Cloned glutamate receptors | Q29619950 | ||
| Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate | Q29620128 | ||
| N-methyl-D-aspartate receptor-mediated mitochondrial Ca(2+) overload in acute excitotoxic motor neuron death: a mechanism distinct from chronic neurotoxicity after Ca(2+) influx | Q32063589 | ||
| Glutamate dehydrogenase and aspartate aminotransferase in leukocytes of patients with motor neuron disease | Q45238051 | ||
| ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. | Q46135324 | ||
| Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice | Q46254778 | ||
| GluR2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis. | Q46617278 | ||
| CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients | Q47631709 | ||
| Calcium dynamics and buffering in motoneurones of the mouse spinal cord | Q48089713 | ||
| 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla | Q48161413 | ||
| Brain glutamate deficiency in amyotrophic lateral sclerosis | Q48180224 | ||
| Neurological dysfunctions in mice expressing different levels of the Q/R site-unedited AMPAR subunit GluR-B. | Q48242571 | ||
| The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical study. | Q48378456 | ||
| Endogenous calcium buffering in motoneurones of the nucleus hypoglossus from mouse | Q48423445 | ||
| Developmental change of endogenous glutamate and gamma-glutamyl transferase in cultured cerebral cortical interneurons and cerebellar granule cells, and in mouse cerebral cortex and cerebellum in vivo | Q48477384 | ||
| Interaction between beta-N-methylamino-L-alanine and excitatory amino acid receptors in brain slices and neuronal cultures. | Q48669893 | ||
| Reductions in acidic amino acids andN-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS | Q48673714 | ||
| Differential expression of Group I metabotropic glutamate receptors in motoneurons at low and high risk for degeneration in ALS. | Q48824219 | ||
| Enhanced LTP in mice deficient in the AMPA receptor GluR2. | Q48875091 | ||
| Neurotoxic effects of excitatory amino acids in the mouse spinal cord: quisqualate and kainate but not N-methyl-D-aspartate induce permanent neural damage | Q48880347 | ||
| SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter | Q48918632 | ||
| Different receptors mediate motor neuron death induced by short and long exposures to excitotoxicity | Q49119317 | ||
| Abnormal glutamate metabolism in amyotrophic lateral sclerosis. | Q51628220 | ||
| Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. | Q52114306 | ||
| 2-Amino-3-(methylamino)-propanoic acid (BMAA) in cycad flour: an unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. | Q52485971 | ||
| A neurophysiological analysis of the effect of kainic acid on nerve fibres and terminals in the cat spinal cord. | Q53857562 | ||
| Studies on the etiology and pathogenesis of motor neuron diseases. II. Clinical and electrophysiologic features of pyramidal dysfunction in macaques fed Lathyrus sativus and IDPN. | Q54127059 | ||
| Intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis | Q56804143 | ||
| Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration | Q57244966 | ||
| Neuroprotection by metabotropic glutamate receptor agonists on kainate-induced degeneration of motor neurons in spinal cord slices from adult rat | Q57744879 | ||
| Excitotoxic Death of a Subset of Embryonic Rat Motor Neurons In Vitro | Q58055965 | ||
| The role of excitotoxicity in neurodegenerative disease: implications for therapy | Q33639170 | ||
| Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). | Q34010341 | ||
| Expression of metabotropic glutamate receptor mRNAs in the human spinal cord: implications for selective vulnerability of spinal motor neurons in amyotrophic lateral sclerosis | Q34089214 | ||
| Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded | Q34175381 | ||
| Calbindin D-28k and parvalbumin in the rat nervous system | Q34224142 | ||
| Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis | Q34300016 | ||
| Excitatory amino acids as a final common pathway for neurologic disorders. | Q34321926 | ||
| Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. | Q34382218 | ||
| The tetrameric structure of a glutamate receptor channel | Q34470732 | ||
| Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons | Q34511996 | ||
| Glutamate neurotoxicity and diseases of the nervous system | Q34560997 | ||
| Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis | Q34736976 | ||
| Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis | Q34936454 | ||
| Cloning by functional expression of a member of the glutamate receptor family | Q35164492 | ||
| Excitatory amino acid neurotoxicity and neurodegenerative disease | Q37989602 | ||
| Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced | Q39531608 | ||
| The TINS/TiPS Lecture the molecular biology of mammalian glutamate receptor channels | Q40492175 | ||
| Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid | Q41235578 | ||
| The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis | Q41413618 | ||
| Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit | Q41649334 | ||
| Lathyrism: evidence for role of the neuroexcitatory aminoacid BOAA. | Q42201775 | ||
| Specific antagonism of excitotoxic action of 'uncommon' amino acids assayed in organotypic mouse cortical cultures | Q42208637 | ||
| Comparative toxicities of alpha- and beta-N-oxalyl-L-alpha, beta-diaminopropionic acids to rat spinal cord | Q42227699 | ||
| A family of glutamate receptor genes: evidence for the formation of heteromultimeric receptors with distinct channel properties | Q42404340 | ||
| Glial cells potentiate kainate-induced neuronal death in a motoneuron-enriched spinal coculture system. | Q42461887 | ||
| ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis | Q42482097 | ||
| Elevated cortical extracellular fluid glutamate in transgenic mice expressing human mutant (G93A) Cu/Zn superoxide dismutase | Q42485699 | ||
| Calcium dynamics and buffering in oculomotor neurones from mouse that are particularly resistant during amyotrophic lateral sclerosis (ALS)-related motoneurone disease | Q42488690 | ||
| Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis | Q43569621 | ||
| EAAT1 and EAAT2 immunoreactivity in transgenic mice with a G93A mutant SOD1 gene | Q43627183 | ||
| Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes. | Q43774336 | ||
| Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels | Q43809083 | ||
| GLT-1 glutamate transporter levels are unchanged in mice expressing G93A human mutant SOD1. | Q43854053 | ||
| Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease | Q43931211 | ||
| Protective effect of parvalbumin on excitotoxic motor neuron death. | Q43939469 | ||
| An alpha-mercaptoacrylic acid derivative (PD150606) inhibits selective motor neuron death via inhibition of kainate-induced Ca2+ influx and not via calpain inhibition | Q43977407 | ||
| Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice | Q43977943 | ||
| Minocycline delays disease onset and mortality in a transgenic model of ALS. | Q44024931 | ||
| Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis | Q44149270 | ||
| Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice | Q44547353 | ||
| A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis | Q44562245 | ||
| Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model | Q45007472 | ||
| P433 | issue | 3-4 | |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| excitotoxicity | Q901117 | ||
| P304 | page(s) | 147-159 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Neurodegenerative Diseases | Q15764918 |
| P1476 | title | Excitotoxicity and amyotrophic lateral sclerosis | |
| P478 | volume | 2 |
| Q28079299 | A Case for Microtubule Vulnerability in Amyotrophic Lateral Sclerosis: Altered Dynamics During Disease |
| Q43011186 | A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis |
| Q38092021 | A review of experimental research on herbal compounds in amyotrophic lateral sclerosis |
| Q92187628 | ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? |
| Q38741121 | Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis |
| Q36302933 | Alterations of striatal glutamate transmission in rotenone-treated mice: MRI/MRS in vivo studies |
| Q39217922 | Altered astrocytic response to activation in SOD1(G93A) mice and its implications on amyotrophic lateral sclerosis pathogenesis |
| Q55877676 | Amyotrophic lateral sclerosis |
| Q48139092 | Antagonistic molecular interactions of photosynthetic pigments with molecular disease targets: a new approach to treat AD and ALS. |
| Q60950974 | Astrocyte-Mediated Neuromodulatory Regulation in Preclinical ALS: A Metadata Analysis |
| Q38109828 | Astrocytic vesicle mobility in health and disease. |
| Q37990880 | Axonal degeneration as a therapeutic target in the CNS. |
| Q43274871 | Branched-chain amino acids induce neurotoxicity in rat cortical cultures |
| Q35772761 | Chronic excitotoxin-induced axon degeneration in a compartmented neuronal culture model |
| Q45332429 | Cumulative effect of 5 daily sessions of θ burst stimulation on corticospinal excitability in amyotrophic lateral sclerosis |
| Q34006224 | D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis |
| Q33789174 | Disrupted glutamate transporter expression in the spinal cord with acute flaccid paralysis caused by West Nile virus infection |
| Q42908670 | Downregulation of the potassium chloride cotransporter KCC2 in vulnerable motoneurons in the SOD1-G93A mouse model of amyotrophic lateral sclerosis |
| Q26753110 | Dysregulated axonal RNA translation in amyotrophic lateral sclerosis |
| Q35951394 | Effect of prolonged riluzole exposure on cultured motoneurons in a mouse model of ALS. |
| Q37909351 | Emerging drugs for amyotrophic lateral sclerosis |
| Q34961354 | Enhanced neuroinflammation and pain hypersensitivity after peripheral nerve injury in rats expressing mutated superoxide dismutase 1. |
| Q96303459 | Exploring Sphingolipid Implications in Neurodegeneration |
| Q93108989 | Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases |
| Q33292690 | GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. |
| Q36637186 | Inducing Chronic Excitotoxicity in the Mouse Spinal Cord to Investigate Lower Motor Neuron Degeneration |
| Q33746289 | Modelling amyotrophic lateral sclerosis: progress and possibilities |
| Q36710448 | Modulation of vascular endothelial growth factor (VEGF) expression in motor neurons and its electrophysiological effects |
| Q39985079 | Molecular mechanisms of interaction between the neuroprotective substance riluzole and GABA(A)-receptors |
| Q37952528 | Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis |
| Q37538542 | Motor neurons derived from ALS-related mouse iPS cells recapitulate pathological features of ALS. |
| Q45881781 | Multifactorial Gene Therapy Enhancing the Glutamate Uptake System and Reducing Oxidative Stress Delays Symptom Onset and Prolongs Survival in the SOD1-G93A ALS Mouse Model |
| Q49342725 | Neurobrucellosis presenting as clinically definite amyotrophic lateral sclerosis |
| Q38051910 | Neurodegeneration as an RNA disorder |
| Q90359231 | Neurodegenerative diseases: model organisms, pathology and autophagy |
| Q39157766 | Neuronal Dysfunction in iPSC-Derived Medium Spiny Neurons from Chorea-Acanthocytosis Patients Is Reversed by Src Kinase Inhibition and F-Actin Stabilization. |
| Q27004431 | Novel molecular biomarkers at the blood-brain barrier in ALS |
| Q34399203 | Persistent inward currents in spinal motoneurons: important for normal function but potentially harmful after spinal cord injury and in amyotrophic lateral sclerosis |
| Q34016411 | Physical activity as an exogenous risk factor in motor neuron disease (MND): a review of the evidence |
| Q93079386 | Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis |
| Q28473241 | Riluzole increases the amount of latent HSF1 for an amplified heat shock response and cytoprotection |
| Q45148790 | Split hand syndrome in amyotrophic lateral sclerosis: different excitability changes in the thenar and hypothenar motor axons |
| Q37871837 | State of the art and the dark side of amyotrophic lateral sclerosis. |
| Q36494315 | State of the field: An informatics-based systematic review of the SOD1-G93A amyotrophic lateral sclerosis transgenic mouse model |
| Q36961660 | Survey of ALS-associated factors potentially promoting Ca2+ overload of motor neurons |
| Q42395440 | The fraction of activated N-methyl-D-aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole |
| Q38065343 | Understanding ALS: new therapeutic approaches. |
| Q33418312 | Upregulation of alpha7 Nicotinic Receptors by Acetylcholinesterase C-Terminal Peptides |
| Q24613053 | Upregulation of the E3 ligase NEDD4-1 by oxidative stress degrades IGF-1 receptor protein in neurodegeneration |
| Q33657315 | Wallerian-like axonal degeneration in the optic nerve after excitotoxic retinal insult: an ultrastructural study |
Search more.